Orbital Therapeutics
About Orbital Therapeutics
A private biotech developing RNA-based medicines designed to reprogram cells in vivo, treating diseases at their source.
Business Information
Target Customers
Industry Categories
Business Model
Funding Timeline
| Round | Date | Amount | Investors |
|---|---|---|---|
| Series A | Oct 10, 2025 | $270.0M | Unknown |
Founders
No founder information available.
Investors
No investor information available.
Recent Mentions
Bristol Myers Squibb agreed to acquire Orbital Therapeutics, a private biotech developing RNA-based medicines, for $1.5 billion, extending a wave of major biotech deals this year. Founded in 2022, Orbital raised $270 million in a 2023 Series A round. Its lead candidate, OTX-201,
Bristol Myers Squibb agreed to acquire Orbital Therapeutics, a private biotech developing RNA-based medicines, for $1.5 billion, extending a wave of major biotech deals this year. Founded in 2022, Orbital raised $270 million in a 2023 Series A round. Its lead candidate, OTX-201,
Similar Startups
Odyssey Therapeutics
88% matchOdyssey Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the stand...
Rui Therapeutics
88% matchRui Therapeutics is a biotechnology startup focused on developing innovative therapies for various d...
Odyssey_Tx
88% matchPrecision immunomodulators for oncology and immunity
Star Therapeutics
88% matchStar Therapeutics is a biotechnology company focused on developing innovative therapies for various ...